Merrimack Pharmaceuticals Inc. Reports First Quarter 2013 Financial Results
5/13/2013 9:39:28 AM
More...
|
Merrimack Pharmaceuticals Inc. Announces Timing of First Quarter 2013 Investor Conference Call
4/30/2013 2:32:43 PM
More...
|
Merrimack Pharmaceuticals Inc. Completes Enrollment of Second Cohort in Phase 2 Study of MM-121 in Non-Small Cell Lung Cancer
4/29/2013 11:33:03 AM
More...
|
Merrimack Pharmaceuticals Inc.' Preclinical Research Shows MM-111 Restores Sensitivity to Chemotherapy and HER2-targeted Treatment in Gastric Cancer Model
4/10/2013 9:59:55 AM
More...
|
Merrimack Pharmaceuticals Inc.' Preclinical Research Shows MM-121 Restores Sensitivity to Anti-Estrogen Therapy and Delays Onset of Treatment Resistance in ER-Positive Breast Cancer Model
4/8/2013 10:30:13 AM
More...
|
Merrimack Pharmaceuticals Inc. Lung Cancer Drug Fails in One Mid-Stage Trial Group
4/4/2013 9:03:12 AM
More...
|
Merrimack Pharmaceuticals Inc. to Present Preclinical Research on Five Novel Cancer Therapies
4/2/2013 9:57:43 AM
More...
|
Merrimack Pharmaceuticals Inc. Completes Enrollment in a Phase 2 Study of MM-121 in Combination With Paclitaxel in Patients With Platinum-Resistant or Refractory Advanced Ovarian Cancers
3/18/2013 11:35:30 AM
More...
|
Merrimack Pharmaceuticals Inc. Reports Fourth Quarter and Full Year 2012 Financial Results
3/14/2013 11:08:07 AM
More...
|
Merrimack Pharmaceuticals Inc. to Present Preclinical Data on Bispecific Antibody MM-111 in ErbB2-Positive Gastric Cancers
1/23/2013 8:50:35 AM
More...
|
|